171 related articles for article (PubMed ID: 12587622)
1. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Burkhardt O; Borner K; Stass H; Beyer G; Allewelt M; Nord CE; Lode H
Scand J Infect Dis; 2002; 34(12):898-903. PubMed ID: 12587622
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
Stass H; Dalhoff A; Kubitza D; Schühly U
Antimicrob Agents Chemother; 1998 Aug; 42(8):2060-5. PubMed ID: 9687407
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
Stass H; Kubitza D; Schühly U
Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
[TBL] [Abstract][Full Text] [Related]
5. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora.
Beyer G; Hiemer-Bau M; Ziege S; Edlund C; Lode H; Nord CE
Eur J Clin Microbiol Infect Dis; 2000 Jul; 19(7):548-50. PubMed ID: 10968328
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora.
Edlund C; Beyer G; Hiemer-Bau M; Ziege S; Lode H; Nord CE
Scand J Infect Dis; 2000; 32(1):81-5. PubMed ID: 10716083
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.
Lettieri J; Vargas R; Agarwal V; Liu P
Clin Pharmacokinet; 2001; 40 Suppl 1():19-25. PubMed ID: 11352438
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.
Edlund C; Alván G; Barkholt L; Vacheron F; Nord CE
J Antimicrob Chemother; 2000 Nov; 46(5):741-9. PubMed ID: 11062193
[TBL] [Abstract][Full Text] [Related]
10. The influence of age and gender on the pharmacokinetics of moxifloxacin.
Sullivan JT; Lettieri JT; Liu P; Heller AH
Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
Sullivan JT; Woodruff M; Lettieri J; Agarwal V; Krol GJ; Leese PT; Watson S; Heller AH
Antimicrob Agents Chemother; 1999 Nov; 43(11):2793-7. PubMed ID: 10543767
[TBL] [Abstract][Full Text] [Related]
12. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
Stass H; Schühly U; Möller JG; Delesen H
Clin Pharmacokinet; 2001; 40 Suppl 1():49-55. PubMed ID: 11352442
[TBL] [Abstract][Full Text] [Related]
13. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
Stass H; Kubitza D
Clin Pharmacokinet; 2001; 40 Suppl 1():57-62. PubMed ID: 11352443
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.
Siefert HM; Domdey-Bette A; Henninger K; Hucke F; Kohlsdorfer C; Stass HH
J Antimicrob Chemother; 1999 May; 43 Suppl B():69-76. PubMed ID: 10382878
[TBL] [Abstract][Full Text] [Related]
16. Absolute bioavailability of moxifloxacin.
Ballow C; Lettieri J; Agarwal V; Liu P; Stass H; Sullivan JT
Clin Ther; 1999 Mar; 21(3):513-22. PubMed ID: 10321420
[TBL] [Abstract][Full Text] [Related]
17. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.
Kees F; Wellenhofer M; Grobecker H
Infection; 1995; 23(3):168-72. PubMed ID: 7499006
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.
Stass H; Kubitza D
Clin Pharmacokinet; 2001; 40 Suppl 1():63-70. PubMed ID: 11352444
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
Stass H; Kubitza D
J Antimicrob Chemother; 1999 May; 43 Suppl B():83-90. PubMed ID: 10382880
[TBL] [Abstract][Full Text] [Related]
20. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.
Stass H; Sachse R
Clin Pharmacokinet; 2001; 40 Suppl 1():71-6. PubMed ID: 11352445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
